Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

[Infections and fingolimod].
First-line natalizumab in multiple sclerosis: rationale, patient selection, benefits and risks.
Chondroitin sulfate proteoglycans in the nervous system: inhibitors to repair.
Incidence of multiple sclerosis in the United Kingdom : findings from a population-based cohort.
Clinical and immunological follow-up of B-cell depleting therapy in CNS demyelinating diseases.
Combining HLA-DR risk alleles and anti-Epstein-Barr virus antibody profiles to stratify multiple sclerosis risk.
Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis.
Vitamin D receptor binding, chromatin states and association with multiple sclerosis.
Disease Modifying Potential of Glatiramer Acetate in Huntington's Disease.
Neuroenhancement through cognitive training and anodal tDCS in multiple sclerosis.
Co-enzyme Q10 and idebenone use in Friedreich's ataxia.
Genzyme’s Lemtrada™ approved in Australia for treatment of multiple sclerosis
Laquinimod for multiple sclerosis.
[The influence of locomotor treatment using robotic body-weight-supported treadmill training on rehabilitation outcome of patients suffering from neurological disorders].
Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study.
ALAIN01-Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential.
Epstein-Barr virus in the multiple sclerosis brain: a controversial issue--report on a focused workshop held in the Centre for Brain Research of the Medical University of Vienna, Austria.
Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis.
Pelvic Floor Muscle Training With and Without Electrical Stimulation in the Treatment of Lower Urinary Tract Symptoms in Women With Multiple Sclerosis.
Ono to enter license agreements with Merck KGaA
Cranial neuropathies in multiple sclerosis defined by magnetic resonance imaging and fludeoxyglucose f 18 positron emission tomography.
It is better to be in a clinical trial than not: lessons learnt from clinical neurology--the management of acute multiple sclerosis relapses.
Acorda Therapeutics announces top line results of post-marketing commitment study exploring 5 mg dose of dalfampridine-ER
Myasthenia gravis and neuromyelitis optica spectrum disorder: A multicenter study of 16 patients.
Multiparametric MRI correlates of sensorimotor function in the spinal cord in multiple sclerosis.

Pages